CURRENT EVIDENCE FOR LDL CAUSALITY; GOALS AND TARGETS
EAS Academy. Packard C. May 27, 2019; 272706 Disclosure(s): Honoraria /grants from MSD, Amgen, Sanofi, Regeneron, Daiichi-Sankyo
Prof. Chris Packard
Prof. Chris Packard

Access to Premium Content is a benefit of Individual EAS membership. Apply for membership


Access EAS content "anytime, anywhere" with the EAS Academy App for iOS and Android


For any questions contact us at office@eas-society.org

Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies